MicroBiopharm Japan Co.

Iwata, Japan

MicroBiopharm Japan Co.

Iwata, Japan
SEARCH FILTERS
Time filter
Source Type

Patent
B Food Science Co. and Microbiopharm Japan Co. | Date: 2014-12-26

[Problem] To provide an improved -fructofuranosidase which enables the production of kestose with high efficiency while reducing the amount of a by-product such as nystose produced during the production of kestose. [Solution] An improved -fructofuranosidase comprising an amino acid sequence which is produced by introducing an amino acid mutation into an amino acid sequence for a -fructofuranosidase having 60% or higher identity to the amino acid sequence for wild-type -fructofuranosidase which is represented by SEQ ID NO: 2, wherein the amino acid mutation is such a mutation that, when amino acid sequence alignment is performed, a histidine (H) residue corresponding to the position 395 as numbered from the N-terminal of the amino acid sequence for the wild-type fructofuranosidase which is represented by SEQ ID NO: 2 can be replaced by an arginine (R) residue or a lysine (K) residue.


Patent
B Food Science Co. and Microbiopharm Japan Co. | Date: 2014-12-26

[Problem] To provide a production method capable of simply and efficiently producing a fructose-added carbohydrate using -fructofuranosidase. [Solution] A method for producing a fructose-added carbohydrate, said method having a step in which a receptor substrate and a hydrate containing terminal fructose residue are brought into contact with:


Patent
B Food Science Co. and MicroBiopharm Japan Co. | Date: 2016-12-21

[Problem] To provide a production method capable of simply and efficiently producing a fructose-added carbohydrate using -fructofuranosidase. [Solution] A method for producing a fructose-added carbohydrate, said method having a step in which a receptor substrate and a hydrate containing terminal fructose residue are brought into contact with:Escherichia coli expressing an anchor protein for expression on a cell surface and -fructofuranosidase as one polypeptide,a composition including dead cells of the expressing Escherichia coli, ora polypeptide obtained from the expressing Escherichia coli and including an amino acid sequence of -fructofuranosidase.


Patent
B Food Science Co. and MicroBiopharm Japan Co. | Date: 2016-11-02

[Problem] To provide an improved -fructofuranosidase which enables the production of kestose with high efficiency while reducing the amount of a by-product such as nystose produced during the production of kestose. [Solution] An improved -fructofuranosidase comprising an amino acid sequence which is produced by introducing an amino acid mutation into an amino acid sequence for a -fructofuranosidase having 60% or higher identity to the amino acid sequence for wild-type -fructofuranosidase which is represented by SEQ ID NO: 2, wherein the amino acid mutation is such a mutation that, when amino acid sequence alignment is performed, a histidine (H) residue corresponding to the position as numbered from the N-terminal of the amino acid sequence for the wild-type -fructofuranosidase which is represented by SEQ ID NO: 2 can be replaced by an arginine (R) residue or a lysine (K) residue.


Konuki K.,MicroBiopharm Japan Co. | Hirasawa I.,Waseda University
Journal of Crystal Growth | Year: 2013

D-chiro-inositol (DCI) is prepared by the immobilized enzyme reaction which uses myo-inositol (MI) as the substrate and the conversion rate is about 13%. The aim of this study was to develop a separation method for high purity DCI crystals from a reaction solution including low purity DCI only by the crystallization process. We succeeded in separating DCI crystals of 96% purity by water cooling crystallization, but it was presumed that scale-up was difficult. Although we tried anti-solvent crystallization similar to water cooling crystallization, high purity DCI crystals were not obtained. Therefore, we proposed the crystallization separation process by controlling metastable zones. The purity of a desired compound is controlled by this process, because solid-liquid separation is achieved before crystallization of compound in metastable zone. By the crystallization using this method, the DCI crystals of 97% purity were obtained. Although the yield per batch is about 50%, the actual yield is improved as the last mother liquor returns into the process of the following batch. When this process was repeated, the purity and the yield of DCI were reproduced and the robustness of this process was proved. It is expected that scale-up of this process will be successful, and this purification method could be applicable to similar systems such as separation of isomers and analogs. © 2012 Elsevier B.V. All rights reserved.


Konuki K.,MicroBiopharm Japan Co. | Nagai H.,MicroBiopharm Japan Co. | Ito M.,MicroBiopharm Japan Co. | Sameshima T.,MicroBiopharm Japan Co.
Organic Process Research and Development | Year: 2014

(R)-Tetrahydrothiophene-3-ol (1) is a key intermediate in the synthesis of penem-based antibiotics. However, it is a viscous liquid at room temperature, which makes it impossible to purify the (R)-isomer especially in the presence of the (S)-isomer. In this study, we successfully developed a process for producing (R)-alcohol 1 with high optical purity by combining bioconversion and crystallization. (R)-Alcohol 1 was prepared by enantioselective bioreduction which used tetrahydrothiophene-3-one (2) as the substrate, and the optical purity was 70-92% ee. The (R)-alcohol 1 liquid was collected from incubation solution and purified to furnish (R)-alcohol 1 with 98.7% ee by cooling crystallization from organic solvents. The scale-up using common crystallization process was difficult, but we developed a crystallization process that employed a jacketed pressure filtration vessel equipped with an agitator which can be operated under low temperature from crystallization to filtration. This led to the establishment of a process for producing (R)-alcohol 1 with high optical purity, and the validity of this process was proved by the scale-up test. © 2014 American Chemical Society.


Patent
MicroBiopharm Japan Co. | Date: 2015-05-20

The present invention provides a method for producing cis-5-hydroxy-L-pipecolic acid. In the production method of the present invention, a gene recombinant microorganism enabling direct production of cis-5-hydroxy-L-pipecolic acid can be used. The present invention also provides such a gene recombinant microorganism. A preferred embodiment of the present invention is characterized in that a gene recombinant microorganism having DNAs encoding proteins involved in the biosynthesis of L-pipecolic acid and a DNA encoding a protein having the L-pipecolic acid cis-5-hydroxylase activity is cultured in a medium, and cis-5-hydroxy-L-pipecolic acid is collected from the medium.


Patent
MicroBiopharm Japan Co. | Date: 2013-06-12

A method for producing cis-5-hydroxy-L-pipecolic acid is described. A gene recombinant microorganism enabling direct production of cis-5-hydroxy-L-pipecolic acid can be used in the method. Also described is a gene recombinant microorganism. In particular, it is described that a gene recombinant microorganism having DNAs encoding proteins involved in the biosynthesis of L-pipecolic acid and a DNA encoding a protein having the L-pipecolic acid cis-5-hydroxylase activity is cultured in a medium, and cis-5-hydroxy-L-pipecolic acid is collected from the medium.


Patent
Eisai R&D Management Co. and MicroBiopharm Japan Co. | Date: 2013-01-16

The nucleotide sequence of a DNA involved in the biosynthesis of herboxidiene was determined. Utilizing this DNA, herboxidiene and analogues thereof can be efficiently produced.


Konuki K.,MicroBiopharm Japan Co. | Nagai H.,MicroBiopharm Japan Co.
Tetrahedron Asymmetry | Year: 2014

(R)-Tetrahydrothiophene-3-ol sulfonyl derivatives 3-19 were prepared by introduction of various sulfonyl groups at the hydroxyl group of (R)-tetrahydrothiophene-3-ol 1 with low enantiomeric purity (68-74% ee). Crystallization was applied to improve their enantiomeric purity. Improvement in enantiomeric purity depended on the introduced sulfonyl group. The enantiomeric purity of enantiomeric sulfonyl derivatives was improved to more than 90% ee by simple crystallization without using seed crystals. These products from crystallization provided not only higher %ee crystals but also a higher %ee mother liquor. The enantiomeric purity of diastereomeric sulfonyl derivatives was improved remarkably, and the product of the derivative 18 provided the mother liquor with 100% de. Crystallization of these sulfonyl derivatives showed a novel and interesting feature that mother liquors with high enantiomeric purity were obtained in many cases. © 2014 Elsevier Ltd. All rights reserved.

Loading MicroBiopharm Japan Co. collaborators
Loading MicroBiopharm Japan Co. collaborators